Prior Radiation in Subjects Who Were Treated With Toca 511 and Toca FC Across 3 Toca 511 Phase 1 Trials

被引：0

作者：

Cloughesy, T. F. ^{[1
]}

Aghi, M. ^{[2
]}

Bota, D. ^{[3
]}

Chen, C. ^{[4
]}

Elder, J. B. ^{[5
]}

Kalkanis, S. N. ^{[6
]}

Kaptain, G. J. ^{[7
]}

Kesari, S. ^{[8
,9
]}

Landolfi, J. ^{[10
]}

Mikkelsen, T. ^{[6
]}

Portnow, J. ^{[11
]}

Robbins, J. M. ^{[12
]}

Ostertag, D. ^{[12
]}

Chu, A. ^{[12
]}

Huang, T. ^{[12
]}

Vogelbaum, M. A. ^{[13
]}

机构：

[1] Univ Calif Los Angeles, Los Angeles, CA USA

[2] UCSF, San Francisco, CA USA

[3] UCI, Irvine, CA USA

[4] Univ Calif San Diego, La Jolla, CA 92093 USA

[5] Ohio State Univ, Columbus, OH 43210 USA

[6] Henry Ford Hosp, Detroit, MI 48202 USA

[7] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[8] Univ Calif San Diego, San Diego, CA USA

[9] John Wayne Canc Inst, Santa Monica, CA USA

[10] JFK Med Ctr, Edison, NJ USA

[11] City Hope Natl Med Ctr, Duarte, CA USA

[12] Tocagen Inc, San Diego, CA USA

[13] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA

来源：

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2016年 / 96卷 / 02期

关键词：

D O I：

10.1016/j.ijrobp.2016.06.758

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2160

引用

页码：E66 / E67

页数：2

共 50 条

[21] EXTENDED BENEFITS IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA THAT CONTINUOUSLY RECEIVE TOCA FC AFTER TOCA 511 TREATMEN
Walbert, Tobias
Damek, Denise
Martinez, Nina L.
Piccioni, David
Singer, Samuel
Cloughesy, Timothy
NEURO-ONCOLOGY, 2021, 23 : 58 - 59
[22] ADMINISTRATION OF TOCA 511 TO SUBJECTS WITH RECURRENT HGG UNDERGOING REPEAT RESECTION
Cloughesy, Timothy F.
Kesari, Santosh
Kalkanis, Steven
Mikkelsen, Tom
Landolfi, Joseph
Elder, J. Bradley
Liau, Linda M.
Chen, Clark C.
Bloomfield, Stephen
Piccioni, David
Chiocca, E. Antonio
Foltz, Greg
Robbins, Joan M.
Ostertag, Derek
Jolly, Doug J.
Ibanez, Carlos
Pertschuk, Dan
Pan, Christine
Vogelbaum, Michael A.
NEURO-ONCOLOGY, 2014, 16
[23] DURABLE RESPONSES OBSERVED IN IDH1 WILDTYPE AND MUTANT RECURRENT HIGH GRADE GLIOMA (rHGG) WITH TOCA 511 & TOCA FC TREATMENT
Cloughesy, Timothy
Landolfi, Joseph
Vogelbaum, Michael
Ostertag, Derek
Elder, Bradley
Carter, Bob
Chen, Clark
Kalkanis, Steven
Lai, Albert
Mikkelsen, Tom
Nghiemphu, Phioanh
Piccioni, David
Accomando, William
Diago, Oscar
Hogan, Daniel
Jolly, Douglas
Wood, Katie
Yang, Liqiang
Gruber, Harry
Das, Asha
Walbert, Tobias
NEURO-ONCOLOGY, 2017, 19 : 26 - 26
[24] COMPLEMENTARY CLINICAL AND ANCILLARY DATA FROM 123 PATIENTS WITH RECURRENT HIGH GRADE GLIOMA FROM THREE PHASE 1 TRIALS OF TOCA 511 AND TOCA FC: UPDATE AND JUSTIFICATION FOR A PHASE 2/3 TRIAL
Aghi, Manish
Vogelbaum, Michael
Kalkanis, Steven
Bota, Daniela
Carter, Bob
Chen, Clark
Elder, Bradley
Engh, Johnathan
Goldlust, Samuel
Kaptain, George
Kesari, Santosh
Landolfi, Joseph
Liau, Linda
Mikkelsen, Tom
Piccioni, David
Portnow, Jana
Singer, Samuel
Walbert, Tobias
Gruber, Harry
Ibanez, Carlos
Jolly, Douglas
Mitchell, Leah
Ostertag, Derek
Shorr, Jolene
Yang, Liqiang
Das, Asha
Cloughesy, Timothy
NEURO-ONCOLOGY, 2016, 18 : 18 - 18
[25] Administration of Toca 511 to subjects with recurrent HGG undergoing repeat resection
Vogelbaum, Michael A.
Cloughesy, Timothy
Landolfi, Joseph
Mikkelsen, Tom
Elder, J. Bradley
Kesari, Santosh
Cobbs, Charles
Skillings, Jamey
Jolly, Douglas
Robbins, Joan
Ostertag, Derek
Ibanez, Carlos
JOURNAL OF NEURO-ONCOLOGY, 2015, 122 (03) : 619 - 619
[26] EVIDENCE SUPPORTINGMECHANISMOFACTIONAND DRUG ACTIVITY IN PHASE I TRIAL OF PATIENTS WITH RECURRENT HIGH GRADE GLIOMA ADMINISTERED TOCA 511 AT SURGICAL RESECTION FOLLOWED BY TOCA FC
Cloughesy, Timothy F.
Liau, Linda M.
Chiocca, E. Antonio
Jolly, Douglas J.
Robbins, Joan M.
Ostertag, Derek
Ibanez, Carlos E.
Gruber, Harry E.
Kasahara, Noriyuki
Vogelbaum, Michael A.
Kesari, Santosh
Mikkelsen, Tom
Kalkanis, Steven
Landolfi, Joseph
Bloomfield, Stephen
Foltz, Greg
Pertschuk, Dan
NEURO-ONCOLOGY, 2013, 15 : 69 - 69
[27] Durable complete responses observed in IDH1 mutated high grade glioma at first recurrence undergoing treatment with Toca 511 and Toca FC.
Cloughesy, Timothy Francis
Ostertag, Derek
Landolfi, Joseph C.
Walbert, Tobias
Vogelbaum, Michael A.
Elder, J. Bradley
Bloomfield, Steven
Carter, Bob
Chen, Clark
Kalkanis, Steven N.
Kesari, Santosh
Lai, Albert
Lee, Ian
Liau, Linda M.
Mikkelsen, Tom
Nghiemphu, Phioanh Leia
Piccioni, David Eric
Jolly, Douglas J.
Gruber, Harry E.
Das, Asha
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[28] An Ascending Dose Phase 1 Trial of the Safety and Tolerability of Toca 511 in Subjects with Recurrent High Grade Glioma
Jolly, D. J.
Cloughsey, T. F.
Chang, S. M.
Aghi, M. K.
Vogelbaum, M. A.
Liau, L. M.
Shafa, R.
Kasahara, N.
Ibanez, C. E.
Perez, O. D.
Robbins, J. M.
Gruber, H. E.
Pertschuk, D.
HUMAN GENE THERAPY, 2011, 22 (10) : A14 - A14
[29] Mechanism of Action of Toca 511 and 5-FC in Animal Models and Cancer Patients
Jolly, Douglas J.
Accomando, William P.
Cloughesy, Timothy F.
Kalkanis, Steven N.
Mikkelsen, Tom
Landolfi, Joseph
Carter, Bob
Chen, Clark C.
Vogelbaum, Michael A.
Elder, James
Piccioni, David
Walbert, Tobias
Hogan, Daniel
Diago, Oscar
Kheoh, Thian
Haghighi, Ali
Gammon, Dawn
Montellano, Tiffany
Kasahara, Noriyuki
Rodriguez-Aguirre, Maria
Mendoza, Daniel
Gruber, Harry E.
Ibanez, Carlos
Ostertag, Derek
MOLECULAR THERAPY, 2019, 27 (04) : 4 - 4
[30] Long-Term Follow-Up Data from 126 Patients with Recurrent High Grade Glioma from Three Phase 1 Trials of Toca 511 and Toca FC: Update and Justification for a Phase 2/3 Trial
Jolly, Doug J.
Aghi, Manish
Vogelbaum, Michael A.
Kalkanis, Steven N.
Bota, Daniela
Chen, Clark C.
Carter, Bob
Elder, Brad
Engh, Johnathan
Goldlust, Samuel A.
Kaptain, George J.
Kesari, Santosh
Landolfi, Joseph
Liau, Linda M.
Mikkelsen, Tom
Piccioni, David
Portnow, Jana
Singer, Samuel
Walbert, Tobias
Gruber, Harry
Ibanez, Carlos
Mitchell, Leah
Ostertag, Derek
Shorr, Jolene S.
Yang, Liqiang
Das, Asha
Cloughesy, Timothy F.
MOLECULAR THERAPY, 2017, 25 (05) : 24 - 25

← 1 2 3 4 5 →